Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases –
— 霍伊特先生擁有二十多年的成功商業經驗，重點是罕見病 —
BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently announced data support the potential for STK-001 to be the first disease-modifying medicine for the treatment of Dravet syndrome.
馬薩諸塞州貝德福德--(美國商業資訊)--2024年4月17日-- Stoke Therapeutics, Inc 納斯達克股票代碼：STOK）是一家生物技術公司，致力於通過使用基於RNA的藥物上調蛋白質表達來解決嚴重疾病的根本原因，該公司今天宣佈任命傑森·霍伊特爲首席商務官。霍伊特先生在領先的生物製藥公司成功規劃和執行商業戰略方面擁有20多年的經驗。作爲首席商務官和斯托克領導團隊成員，霍伊特先生將負責監督公司針對 STK-001 的全球商業戰略。最近公佈的數據支持 STK-001 有可能成爲第一種治療德拉維特綜合徵的疾病改善藥物。
"Jason brings deep expertise and a proven track record in successfully driving commercial strategies for novel new medicines and accelerating growth for companies as they transition to the commercial stage," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "Jason's experience building and leading teams, particularly in the area of rare disease, comes at the perfect time for Stoke as we plan for our registrational study of STK-001 and set our sights on the future where we aim to deliver the first potential disease-modifying medicine to patients with Dravet syndrome."
Stoke Therapeutics首席執行官愛德華·凱伊醫學博士表示：“傑森在成功推動新藥商業戰略和加速公司過渡到商業階段的增長方面擁有深厚的專業知識和良好的往績記錄。”“傑森積累和領導團隊的經驗，尤其是在罕見病領域的經驗，正是斯托克的最佳時機，因爲我們計劃進行 STK-001 註冊研究，並着眼於未來，我們的目標是向德拉維特綜合徵患者提供第一種潛在的疾病改善藥物。”
"The recent data from the studies of STK-001 suggest that Stoke has the opportunity to change the way Dravet syndrome is treated by targeting the underlying cause of the disease, not just the symptoms," said Mr. Hoitt. "I have been fortunate to have worked on some incredibly important advances in the treatment of severe diseases and look forward to bringing that experience and passion to Stoke. I am excited by the opportunity to build on the strong foundation of scientific innovation and clinical execution as we prepare the company to successfully conduct a registrational study and commercialize STK-001 and other potential new medicines in the future."
霍伊特說：“最近的 STK-001 研究數據表明，斯托克有機會通過靶向該疾病的根本原因，而不僅僅是症狀，來改變德拉維特綜合徵的治療方式。”“我很幸運能夠在嚴重疾病治療方面取得一些非常重要的進展，並期待將這種經驗和激情帶給斯托克。我很高興有機會在科學創新和臨床執行的堅實基礎上再接再厲，爲公司未來成功開展註冊研究和商業化 STK-001 和其他潛在新藥做好準備。”
Prior to joining Stoke, Mr. Hoitt served as Chief Commercial Officer at Provention Bio and led all commercial efforts including pre-launch and launch strategy and execution for Tzield(teplizumab-mzwv), the first drug approved to address the underlying autoimmune cause of type 1 diabetes. Prior to Provention Bio, Mr. Hoitt served as Chief Commercial Officer at Dova Pharmaceuticals and led all commercial efforts including launch strategy and execution for DOPTELET (avatrombopag) for chronic immune thrombocytopenia. Prior to Dova Pharmaceuticals, Mr. Hoitt was a member of the commercial leadership team at Insmed Incorporated, serving as a Vice President and Head of Sales. Mr. Hoitt also held senior sales, marketing and medical affairs roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences. Mr. Hoitt has held integral roles in the launch of several innovative medicines, including Arikayce (Insmed), Exondys 51 (Sarepta), and Incivek (Vertex). Mr. Hoitt holds a B.A. from the College of the Holy Cross.
在加入Stoke之前，霍伊特先生曾在Provention Bio擔任首席商務官，領導了所有商業工作，包括Tzield的預發佈和發佈策略以及執行（teplizumab-mzwv），第一種獲准治療1型糖尿病潛在自身免疫原因的藥物。在加入 Provention Bio 之前，霍伊特先生曾在 Dova Pharmicals 擔任首席商務官，領導所有商業工作，包括DOPTELET的發佈戰略和執行 （avatrombopag）用於治療慢性免疫性血小板減少症。在加入多瓦製藥之前，霍伊特先生是Insmed Incorporated商業領導團隊的成員，曾擔任副總裁兼銷售主管。霍伊特先生還曾在Sarepta Therapeutics、Vertex Pharmicals和吉利德科學公司擔任高級銷售、營銷和醫療事務職務。霍伊特先生在幾種創新藥物的推出中發揮了不可或缺的作用，包括Arikayce（Insmed）、Exondys 51（Sarepta）和Incivek（Vertex）。霍伊特先生擁有聖十字學院的學士學位。
Effective on April 15, 2024, Stoke granted Mr. Hoitt a stock option to purchase an aggregate of 265,000 shares of common stock, as a material inducement to his employment in accordance with Nasdaq Listing Rule 5635(c)(4).
根據納斯達克上市規則第5635（c）（4），斯托克自2024年4月15日起授予霍伊特先生購買總額爲26.5萬股普通股的股票期權，以此作爲其就業的實質性誘因。
The stock option that was granted has an exercise price of $12.21 per share, which is equal to the closing price of Stoke's common stock on April 15, 2024. The option will vest over a 4-year period, with 1/4th of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the option over the following 36 months, subject to Mr. Hoitt's continued employment with Stoke on such vesting dates. The option has a term of 10 years and is subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.
授予的股票期權的行使價爲每股12.21美元，等於斯托克普通股在2024年4月15日的收盤價。該期權將在 4 年內歸屬，其中 1/4第四 在適用的歸屬開始日一週年之際歸屬的期權所依據的股份以及此後按1/48的利率每月歸屬的剩餘股份第四 在接下來的36個月中，該期權所依據的股份，前提是霍伊特先生在該歸屬日期繼續在斯托克工作。該期權的期限爲10年，受2023年激勵計劃和涵蓋該贈款的股票期權協議的條款和條件的約束。
About Stoke Therapeutics
關於斯托克療法
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke's first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.
Stoke Therapeutics（納斯達克股票代碼：STOK）是一家生物技術公司，致力於通過使用基於RNA的藥物上調蛋白質表達來解決嚴重疾病的根本原因。斯托克正在使用斯托克專有的TANGO（靶向增強核基因輸出）方法，開發反義寡核苷酸（ASO），以選擇性地恢復蛋白質水平。斯托克的第一個化合物 STK-001 正在臨床測試中，用於治療德拉維特綜合徵，這是一種嚴重的進行性遺傳性癲癇。Dravet綜合徵是單倍體功能不全引起的衆多疾病之一，在這種疾病中，正常蛋白質水平的損失約50％會導致疾病。斯托克正在開發用於治療常染色體顯性視神經萎縮（ADOA）的 STK-002，這是最常見的遺傳性視神經疾病。斯托克最初的重點是單倍體功能不全以及中樞神經系統和眼睛的疾病，儘管概念驗證已在其他器官、組織和系統中得到證實，這支持了其相信其專有方法具有廣泛潛力的信念。斯托克總部位於馬薩諸塞州貝德福德，在馬薩諸塞州劍橋設有辦事處。欲了解更多信息，請訪問 https://www.stoketherapeutics.com/。
Cautionary Note Regarding Forward-Looking Statements
關於前瞻性陳述的警示說明
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the ability of STK-001 to treat the underlying cause of Dravet syndrome, and the timing and expected progress of clinical trials, regulatory decisions and successful development of STK-001. Statements including words such as "will," "expect," "plan," and "potential" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the Company's ability to advance, obtain regulatory approval of, and ultimately commercialize its product candidates, including STK-001; positive results in a clinical trial may not be replicated in subsequent trials; successes in early stage trials may not be predictive of results in later stage trials; the Company's ability to fund development activities and achieve development goals; and other risks and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, its quarterly reports on Form 10-Q, and the other documents it files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
本新聞稿包含1995年《私人證券訴訟改革法》“安全港” 條款所指的前瞻性陳述，包括但不限於 STK-001 治療德拉維特綜合徵根本原因的能力，以及臨床試驗、監管決策和成功開發 STK-001 的時間和預期進展。包含 “將”、“期望”、“計劃” 和 “潛力” 等詞語的陳述以及未來時態陳述均爲前瞻性陳述。這些前瞻性陳述涉及風險和不確定性以及假設，如果事實證明不正確或未完全實現，則可能導致結果與此類前瞻性陳述所表達或暗示的結果存在重大差異，包括但不限於與以下方面相關的風險和不確定性：公司推進、獲得監管部門批准並最終將其商業化的能力，包括 STK-001；臨床試驗的積極結果可能無法在後續試驗中複製；早期階段試驗可能無法預測後期試驗的結果；公司爲發展活動提供資金和實現發展目標的能力；以及公司截至2023年12月31日止年度的10-K表年度報告、10-Q表季度報告及其不時向美國證券交易委員會提交的其他文件中 “風險因素” 標題下描述的其他風險和不確定性。這些前瞻性陳述僅代表截至本新聞稿發佈之日，公司沒有義務修改或更新任何前瞻性陳述以反映本新聞稿發佈之日之後的事件或情況。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417733047/en/
Stoke Media & Investor Contacts:
Dawn Kalmar
Chief Communications Officer
dkalmar@stoketherapeutics.com
781-303-8302
Eric Rojas
Vice President, Investor Relations
IR@stoketherapeutics.com
617-312-2754
Stoke 媒體與投資者聯繫人：
黎明卡爾瑪
首席傳播官
dkalmar@stoketherapeutics.com
781-303-8302
埃裏克·羅哈斯
投資者關係副總裁
IR@stoketherapeutics.com
617-312-2754
Source: Stoke Therapeutics, Inc.
來源：Stoke Therapeutics, Inc
譯文內容由第三人軟體翻譯。